6533b838fe1ef96bd12a5106
RESEARCH PRODUCT
Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy.
Anna EberingAri Waismansubject
Multiple SclerosisCentral nervous systemAxonal lossDiseaseCD8-Positive T-LymphocytesCD8+ T cellsanti-CD20 therapy03 medical and health sciences0302 clinical medicineImmune systemImmunology and InflammationAntigenmedicineHumansMyelin SheathMultidisciplinarybusiness.industryMultiple sclerosisExperimental autoimmune encephalomyelitisBiological Sciencesmedicine.diseaseAntigens CD20medicine.anatomical_structureImmunizationImmunologybusinessmyelin antigen030217 neurology & neurosurgery030215 immunologydescription
Significance Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. CD8+ T cells have been strongly implicated in MS pathogenesis, but it is unclear whether myelin is a CD8+ T cell autoantigenic target in MS. This study demonstrated that while myelin-specific CD8+ T cells are present at similar frequencies in untreated MS patients and healthy subjects, the proportion of memory and CD20-expressing myelin-specific CD8+ T cells was increased in MS patients, suggesting prior antigen encounter. This activated phenotype was reversible as the memory and CD20-expressing populations of certain myelin-specific CD8+ T cells were reduced following anti-CD20 treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-12-04 | Proceedings of the National Academy of Sciences of the United States of America |